{"nctId":"NCT00252733","briefTitle":"Diabetic Retinopathy Candesartan Trials","startDateStruct":{"date":"2001-06"},"conditions":["Type 1 Diabetes"],"count":5238,"armGroups":[{"label":"1","type":"NO_INTERVENTION","interventionNames":[]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: candesartan cilexetil"]}],"interventions":[{"name":"candesartan cilexetil","otherNames":["ATACAND"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 1 diabetes diagnosed before age of 36 years and in need for continuous insulin treatment within 1 year of diagnosis of diabetes are included.\n* Duration of diabetes for \\> 1 year and \\< 15 years with stable diabetic therapy within last 6 months.\n* Patients with untreated resting mean sitting SBP \\< 130 mmHg, mean sitting DBP \\< 85 mmHg and with retinal photograph grading level 10/10 (on ETDRS severity scale).\n\nExclusion Criteria:\n\n* Patients with the following conditions are excluded from participation in the study:\n* Cataract or media opacity of a degree which precludes taking gradable retinal photographs\n* Angle closure glaucoma, which precludes pharmacological dilatation of the pupil\n* History of retinopathy\n* History or presence of clinical significant macular oedema (CSME)\n* History or evidence of photocoagulation of the retina Other retinal conditions which may mask assessment, eg, retinal vein occlusion\n* Positive micral dipstick test\n* Presence of secondary diabetes\n* Pregnant or lactating women or women of child bearing potential not practicing an adequate method of contraception\n* Need of treatment with ACE-inhibitor\n* Haemodynamically significant aortic or mitral valve stenosis\n* Known renal artery stenosis or kidney transplantation\n* Hypersensitivity to study drug\n* Severe concomitant disease which may interfere with the assessment of the patient, eg, malignancy, as judged by the investigator","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With a 2-step or Greater Increase in Early Treatment Diabetic Retinopathy Study (ETDRS) Severity Scale.","description":"Two steps were defined as either a 1-step change in each eye or as a 2-step change in one eye only. ETDRS is a scale with 11 steps (1-11, where a score of 1 represents no retinopathy and a score of 11 represents proliferative retinopathy). A generalized log-rank test was used to test difference between treatments.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"178","spread":"0.071"},{"groupId":"OG001","value":"217","spread":"0.086"}]}]}]},{"type":"SECONDARY","title":"Rate of Change in Urinary Albumin Excretion Rate (UAER).","description":"An estimate of the slope from fitting a linear regression of log(UAER) over time for each patient.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.510","spread":null},{"groupId":"OG001","value":"0.543","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":102,"n":710},"commonTop":["Hypotension"]}}}